英国国际贸易部帮助英国公司在中国取得成功，中国公司在英国设立和投资。它通过促进和融资国际贸易和投资以及促进自由贸易来帮助保护英国和全球繁荣。

在这次独家采访中，她的陛下对国际贸易部的贸易专员John Edwards，讨论了中国的医疗保健和生命科学市场如何迅速增长，并通过增加需求和对法规的变化而导致的。

1. What are the benefits experienced by companies that partner with UK life science companies?

I would say quite simply that UK businesses deliver profit, drive innovation and make a difference.由于英国向新时代迁移到一个新时代，中英商家甚至有机会驾驶更改游戏更改的创新，并对个人，家庭和全球经济产生差异。关于生命科学，英国是一项全球独特的生态生态系统，为生命科学和健康创新，核心优势包括：

• 英国领先的科学人才基础：英国是世界上十大大学的4个临床和健康科学的所在地。在英国发现了4个处方药中的4个中毒。
• 我们的动态和国际生命科学cluster:英国是第三大全球生命科学中心。全球25名全球制药公司和前30名全球Medtech公司在英国存在。
• 英国是世界上最大的综合健康服务的所在地：NHS提供了全国性的研究和证据生成平台，具有独特的数据能力和临床洞察。
• 这是政府和行业在伙伴关系中工作的地方：2017年，英国推出了生命科学产业战略，同意贡献数十亿美元的资金，以使英国保持在生命科学和医疗保健的最前沿。
• 英国有竞争力的商业环境：For pre-revenue biotech companies, UK offers not only world class clinical resources system NHS-NIHR-MHRA, but also a market competitive tax rebate of up to 33% of capital spending on R&D and clinical trials.

2.您认为合作伙伴如何帮助推进英国，中国金博宝188备用地址和世界各地的生命科学？

• Partnership is crucial in the global life sciences industry, such are the scale of global health challenges, from ageing population, growth of non-communicable diseases, and rising expectations of healthcare systems. No issue illustrates this more than the COVID-19 pandemic.The UK and China share common goals when it comes to the essential role of international trade and collaboration to beat the threat of the pandemic and to secure global economic recovery. It is heartening to see that in times of crisis UK and Chinese businesses can continue working together in support of global challenges, like COVID-19.
• 在疫苗和治疗发展的情况下，这将需要各国政府，学术界，工业和医疗组织的集体努力。我们需要各国共同努力，开发和制造疫苗以供应全球人口。英国政府与国际社会合作，支持快速发展和制造安全，有效的疫苗，并确保广泛的公平获得英国和全球疫苗。6月份，英国组织了2020年全球疫苗峰会，帮助保护74亿美元的资金，以支持全球疫苗供应和免疫。
• 在牛津Jenner Institute开发的腺瘤病毒载体碱疫苗是政府，学术界和业务之间的伙伴关系的一个很好的例子。鉴于英国的先进生命科学生态系统，团队已经能够迅速前进。这是七月全球进入第三阶段的第一个疫苗之一。据报道，该项目可在10月份提供应急疫苗。AstraZeneca表示，如果批准，疫苗的总制造能力均以达到20亿剂。 An Imperial College developed RNA vaccine also entered clinical trials in June. Both developments are being supported by c. £130m of UK government funding.

3. The DIT helps UK companies succeed in China, and Chinese companies set up and invest in the UK. What are some of the ongoing UK-China cooperation projects you can tell us about?

• 英国的国际贸易部门欢迎并充分支持中国公司来英国进行合作和投资。来自中国商务部（MOFCOM）的数据表明，英国对欧洲的中国投资最大的股票。并展望未来，英国将仍将成为最开放的经济体之一，开放贸易和投资中国和所有国家。
• The UK and China have ongoing collaboration in many areas of healthcare and life sciences, from the creation of innovation hubs supporting healthcare innovation to pharmaceutical licencing, and most importantly at the moment to vaccine production. Key global players, UK-headquartered AstraZeneca and GlaxoSmithKline are leading the charge.
• On the 6th of August this year, AstraZeneca announced a momentous exclusive framework agreement with KangTai Bio for the license and manufacturing of the Oxford developed COVID-19 vaccine AZD1222. This agreement will ensure the manufacturing of 100 million doses of the vaccine by the end of this year. GSK is also working with Chinese companies Clover Biopharmaceuticals and Xiamen Innovax Biotech on COVID-19 vaccines.
• Two significant cross-border licensing deals were also announced this year. EUSA pharma licensed two of their ready to market rare disease assets SYLVANT and QARZIBA to Beigene, which is a record breaker for upfront payment, while, Mereo Biopharma licensed bispecific antibody Navicixizumab to Oncologie for late stage platinum resistant ovarian cancer. Both companies were participants of the UK pavilion at ChinaBio® Partnering Forum last year.

4.希望扩展到中国的公司面临的一些挑战是什么？他们如何克服？

• UK companies are investing more in China. UK FDI stock in China increased from £10.6bn in 2017 to £16bn in 2018. Data from China’s MOFCOM shows that the UK was the largest Western investor into China in 2018, and the largest European investor into China across much of 2019.
• 当然，虽然在中国市场的英国生命科技公司有巨大的机会，但它的纯粹的大小和复杂性可能是挑战性的。事实上，由于市场的规模，公司通常必须考虑拥有多个代理商或经销商，公司必须考虑在将产品进入市场中的成本。
• DIT中国和其他专家组织的团队随时支持，并建议正在考虑进入中国市场的英国企业。

5.公司希望扩展到中国或希望在中国合作的第一步是什么？英国的DIT如何有助于这些步骤？

• 该公司对中国有兴趣的最佳第一步是与我们的市场专家团队联系。Qionger博士Qionger.he@fco.gov.uk，是DIT中国的Pharma负责人，可以在您的选择上提供初步反馈，包括英国政府支持，以帮助您的公司在中国取得成功。
• I would certainly encourage UK healthcare and life sciences firms to consider the opportunities in China. China’s healthcare and life sciences markets are growing rapidly, driven by increased demand and changes to regulations. Areas of opportunity include new treatments for non-communicable diseases, innovative pharmaceuticals and biotech, genomics, rare diseases, digital health, integrated care, clinical services, medical devices, training and education.
• 中国is rapidly reforming the regulation and reimbursement of pharmaceuticals and medical devices. It is now one of the fastest places in the world to register new drugs. Alignment with international standards and the demand for new treatments is stimulating interest in multi-centre clinical trials.
• 英国政府支持英国商业与商业合作的一个很好的例子是Chinabio本身的工作。英国政府带来了25家公司，包括世界领先的生命科学组织和公司，如癌症研究英国，excientiatia，vaccitech和猫头鹰到Chinabio 2020.英国也建立了一个数字展馆来展示独特的实力和产品英国公司加入中国生物®合作论坛。金博宝188备用地址
• From August, we will host a 6-month series of UK-China virtual investment conferences, roadshows, and pitching sessions with Chinese investors and companies, to stimulate the life sciences dialogue going between the UK and China and to explore cooperation opportunities in this domain.